Brødkrumme Forside Celladon Celladon Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing their oxygen consumption. Lundbeckfonden BioCapital Investeringsår 2010 IPO in 2013 – CLDN (Nasdaq) Lokation La Jolla, California, USA